148 related articles for article (PubMed ID: 35116080)
1. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.
Bruni C; Gentileschi S; Pacini G; Bardelli M; Tofani L; Bartoli F; Baldi C; Cometi L; Fiori G; Nacci F; Cantarini L; Guiducci S; Moggi-Pignone A; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211033679. PubMed ID: 35116080
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
5. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
Tapete G; Bertani L; Pieraccini A; Lynch EN; Giannotta M; Morganti R; Biviano I; Naldini S; Mumolo MG; De Nigris F; Calella F; Bagnoli S; Minciotti M; Maltinti S; Rentini S; Ceccarelli L; Lionetti P; Milla M; Costa F
Inflamm Bowel Dis; 2022 Jan; 28(1):62-69. PubMed ID: 33570142
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
8. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
[TBL] [Abstract][Full Text] [Related]
9. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.
Song SH; Woo SJ
Ocul Immunol Inflamm; 2024 Jan; ():1-5. PubMed ID: 38194436
[TBL] [Abstract][Full Text] [Related]
12. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
13. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
14. Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care.
Redeker I; Moustakis S; Tsiami S; Baraliakos X; Andreica I; Buehring B; Braun J; Kiltz U
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231197087. PubMed ID: 37694183
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
[TBL] [Abstract][Full Text] [Related]
16. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.
Bruni C; Gentileschi S; Pacini G; Baldi C; Capassoni M; Tofani L; Bardelli M; Cometi L; Cantarini L; Nacci F; Vietri M; Bartoli F; Fiori G; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20964031. PubMed ID: 33133246
[TBL] [Abstract][Full Text] [Related]
17. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.
Ribaldone DG; Tribocco E; Rosso C; Armandi A; Vernero M; Bugianesi E; Astegiano M; Saracco GM; Caviglia GP
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362184
[TBL] [Abstract][Full Text] [Related]
18. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB
Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655
[TBL] [Abstract][Full Text] [Related]
19. The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study.
van Adrichem RCS; Voorneveld HJE; Waverijn GJ; Kok MR; Bisoendial RJ
Rheumatol Ther; 2022 Aug; 9(4):1109-1118. PubMed ID: 35655028
[TBL] [Abstract][Full Text] [Related]
20. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]